Defence Financial Statements From 2010 to 2024
| DTCFF Stock | USD 0.41 0.00 0.00% |
Check Defence Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Defence Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Defence financial statements analysis is a perfect complement when working with Defence Therapeutics Valuation or Volatility modules.
Defence |
Defence Therapeutics OTC Stock Shares Outstanding Analysis
Defence Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Defence Therapeutics Shares Outstanding | 37.85 M |
Most of Defence Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Defence Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Defence Therapeutics has 37.85 M of shares currently outstending. This is 79.03% lower than that of the Healthcare sector and 64.58% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 93.38% higher than that of the company.
Defence Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Defence Therapeutics's current stock value. Our valuation model uses many indicators to compare Defence Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Defence Therapeutics competition to find correlations between indicators driving Defence Therapeutics's intrinsic value. More Info.Defence Therapeutics is rated # 2 in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Defence Therapeutics' earnings, one of the primary drivers of an investment's value.About Defence Therapeutics Financial Statements
Defence Therapeutics stakeholders use historical fundamental indicators, such as Defence Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Defence Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Defence Therapeutics' assets and liabilities are reflected in the revenues and expenses on Defence Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Defence Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biologicalbiosimilar therapeutic drugs for cancer and infectious diseases. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada. Defence Therapeutics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Defence OTC Stock
Defence Therapeutics financial ratios help investors to determine whether Defence OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Defence with respect to the benefits of owning Defence Therapeutics security.